Literature DB >> 17222633

Changes in urine markers and symptoms after bladder distention for interstitial cystitis.

Deborah R Erickson1, Allen R Kunselman, Christina M Bentley, Kenneth M Peters, Eric S Rovner, Laurence M Demers, Marcia A Wheeler, Susan K Keay.   

Abstract

PURPOSE: We evaluated changes in urine markers and symptom scores after bladder distention in patients with interstitial cystitis.
MATERIALS AND METHODS: Study subjects were 33 new patients who had undergone no prior interstitial cystitis treatment. Urine specimens were taken before and 1 month after bladder distention. University of Wisconsin symptom scores were done the same day as the urine specimen collection. Urine marker levels and symptom scores before and after distention were compared. Changes in markers were tested for associations with changes in symptom scores and other markers. Markers and specific symptoms before distention were tested for their association with post-distention symptom improvement.
RESULTS: After distention the median total University of Wisconsin score decreased significantly (28.5 before, 20 after, p <0.001). A total of 12 patients (36%) had at least 30% improvement in University of Wisconsin score, and 8 patients (24%) had at least 50% improvement. No pre-distention markers or symptoms predicted which patients would have a good response. There were 2 urine markers that improved significantly after distention: anti-proliferative factor activity (median -96% before, -17% after, p <0.001) and heparin-binding epidermal growth factor-like growth factor levels (median 0.34 ng/mg creatinine before, 4.1 after, p <0.001). None of the changes in urine markers associated with changes in symptom scores.
CONCLUSIONS: The median symptom score for newly diagnosed patients with interstitial cystitis decreased after distention, but only a minority of patients had at least 30% symptom improvement. Bladder distention altered urine anti-proliferative factor activity and heparin-binding epidermal growth factor-like growth factor levels toward normal, but the mechanism of symptom relief after distention is still unknown.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17222633      PMCID: PMC2373609          DOI: 10.1016/j.juro.2006.09.029

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  20 in total

1.  Inflammatory cell types and clinical features of interstitial cystitis.

Authors:  D R Erickson; D A Belchis; D J Dabbs
Journal:  J Urol       Date:  1997-09       Impact factor: 7.450

2.  Do the National Institute of Diabetes and Digestive and Kidney Diseases cystoscopic criteria associate with other clinical and objective features of interstitial cystitis?

Authors:  Deborah R Erickson; John E Tomaszewski; Allen R Kunselman; Christina M Bentley; Kenneth M Peters; Eric S Rovner; Laurence M Demers; Marcia A Wheeler; Susan K Keay
Journal:  J Urol       Date:  2005-01       Impact factor: 7.450

3.  What is the value of cystoscopy with hydrodistension for interstitial cystitis?

Authors:  Derek P Ottem; Joel M H Teichman
Journal:  Urology       Date:  2005-09       Impact factor: 2.649

4.  Psychometric analysis of the University of Wisconsin Interstitial Cystitis Scale: implications for use in randomized clinical trials.

Authors:  J E Goin; D Olaleye; K M Peters; B Steinert; K Habicht; G Wynant
Journal:  J Urol       Date:  1998-03       Impact factor: 7.450

5.  Nitric oxide as an objective marker for evaluation of treatment response in patients with classic interstitial cystitis.

Authors:  Abolfazl Hosseini; Ingrid Ehrén; N Peter Wiklund
Journal:  J Urol       Date:  2004-12       Impact factor: 7.450

6.  Is urine methylhistamine a useful marker for interstitial cystitis?

Authors:  Deborah R Erickson; Allen R Kunselman; Christina M Bentley; Kenneth M Peters; Eric S Rovner; Laurence M Demers; John E Tomaszewski
Journal:  J Urol       Date:  2004-12       Impact factor: 7.450

7.  Activation of the kallikrein kinin system in interstitial cystitis.

Authors:  A Rosamilia; J A Clements; P L Dwyer; M Kende; D J Campbell
Journal:  J Urol       Date:  1999-07       Impact factor: 7.450

8.  Activation of urinary kallikrein in patients with interstitial cystitis.

Authors:  B L Zuraw; S Sugimoto; C L Parsons; T Hugli; M Lotz; J Koziol
Journal:  J Urol       Date:  1994-09       Impact factor: 7.450

9.  Mechanical stretch is a highly selective regulator of gene expression in human bladder smooth muscle cells.

Authors:  Rosalyn M Adam; Samuel H Eaton; Carlos Estrada; Ashish Nimgaonkar; Shu-Ching Shih; Lois E H Smith; Isaac S Kohane; Darius Bägli; Michael R Freeman
Journal:  Physiol Genomics       Date:  2004-10-05       Impact factor: 3.107

10.  The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study.

Authors:  P M Hanno; J R Landis; Y Matthews-Cook; J Kusek; L Nyberg
Journal:  J Urol       Date:  1999-02       Impact factor: 7.450

View more
  19 in total

1.  Bladder Hydrodistention Does Not Result in a Significant Change in Bladder Capacity for Interstitial Cystitis/Bladder Pain Syndrome Patients.

Authors:  Stephen J Walker; Andre Plair; Kshipra Hemal; Carl D Langefeld; Catherine Matthews; Gopal Badlani; Joao Zambon; Heather Heath; Robert J Evans
Journal:  Urology       Date:  2019-07-09       Impact factor: 2.649

Review 2.  Practical use of the new American Urological Association interstitial cystitis guidelines.

Authors:  Renee B Quillin; Deborah R Erickson
Journal:  Curr Urol Rep       Date:  2012-10       Impact factor: 3.092

Review 3.  Painful bladder syndrome: an update and review of current management strategies.

Authors:  Anthony J Dyer; Christian O Twiss
Journal:  Curr Urol Rep       Date:  2014-02       Impact factor: 3.092

4.  Biomarkers for interstitial cystitis/painful bladder syndrome.

Authors:  Shilpa Argade; Christopher Chermansky; Pradeep Tyagi
Journal:  Womens Health (Lond)       Date:  2015-12-23

Review 5.  A systematic review of the literature on cystodistension in bladder pain syndrome.

Authors:  Louise E Olson; James E Dyer; Ahsanul Haq; Jeremy Ockrim; Tamsin J Greenwell
Journal:  Int Urogynecol J       Date:  2017-05-26       Impact factor: 2.894

Review 6.  What's new in the diagnosis and management of painful bladder syndrome/interstitial cystitis?

Authors:  Abhishek Seth; Joel M H Teichman
Journal:  Curr Urol Rep       Date:  2008-09       Impact factor: 3.092

7.  Potassium sensitivity test predicts hydrodistention efficacy in patients with bladder pain syndrome/interstitial cystitis.

Authors:  Ömer Gülpınar; Barış Esen; Çağrı Akpınar; Utku Baklacı; Mehmet İlker Gökce; Evren Süer; Yaşar Bedük
Journal:  Turk J Urol       Date:  2019-11-14

Review 8.  [Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A].

Authors:  B Amend; D Castro-Diaz; E Chartier-Kastler; D De Ridder; K Everaert; M Spinelli; P van Kereebroeck; K-D Sievert
Journal:  Urologe A       Date:  2010-02       Impact factor: 0.639

9.  Management of Symptom Flares and Patient-reported Flare Triggers in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)-Findings From One Site of the MAPP Research Network.

Authors:  H Henry Lai; Joel Vetter; Joseph Song; Gerald L Andriole; Graham A Colditz; Siobhan Sutcliffe
Journal:  Urology       Date:  2019-01-22       Impact factor: 2.649

10.  The Challenges of Interstitial Cystitis: Current Status and Future Prospects.

Authors:  Samuel Belknap; Eric Blalock; Deborah Erickson
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.